Johnson & Johnson’s sNDA for Akeega gets US FDA approval to treat patients with BRCA2-mutated mCSPC: Horsham, Pennsylvania Wednesday, December 17, 2025, 13:00 Hrs [IST] Johnson ...
The firm expects to begin the Phase I trial in HER2-positive breast and gastric cancers in the first half of 2026.
Aldeyra submitted the single successful trial to the FDA over the summer and the agency accepted the resubmitted NDA for ...
The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for Aldeyra’s New Drug Application (NDA) for reproxalap for the treatment of dry ...
Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated pharmaceutical company, announced today that the U.S. Food and ...
REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in preclinical models of asthma, acute lung inflammation and ...
Senores Pharmaceuticals Ltd said it has acquired a Gujarat-based pharmaceutical company along with five of its drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback